The impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection.

dc.contributor.authorPeeters, Pascale
dc.contributor.authorRyan, Kellie
dc.contributor.authorKarve, Sudeep
dc.contributor.authorPotter, Danielle
dc.contributor.authorBaelen, Elisa
dc.contributor.authorRojas-Farreras, Sonia
dc.contributor.authorRodríguez-Baño, Jesús
dc.date.accessioned2025-01-07T16:44:48Z
dc.date.available2025-01-07T16:44:48Z
dc.date.issued2019-01-31
dc.description.abstractThe RECOMMEND study (NCT02364284; D4280R00005) assessed the clinical management patterns and treatment outcomes associated with initial antibiotic therapy (IAT; antibiotics administered ≤48 hours post-initiation of antibiotic therapy) for health care-associated infections across five countries. Data were collected from a retrospective chart review of patients aged ≥18 years with health care-associated complicated intra-abdominal infection (cIAI). Potential risk factors for IAT failure were identified using logistic regression analyses. Of 385 patients with complete IAT data, bacterial pathogens were identified in 270 (70.1%), including Gram-negative isolates in 221 (81.9%) and Gram-positive isolates in 92 (34.1%). Multidrug-resistant (MDR) pathogens were identified in 112 patients (41.5% of patients with a pathogen identified). IAT failure rate was 68.3% and in-hospital mortality rate was 40.8%. Multivariate regression analysis demonstrated three factors to be significantly associated with IAT failure: patients admitted/transferred to the intensive care unit during index hospitalization, isolation of an MDR pathogen and previous treatment with β-lactam antibiotics. We reveal the real-world insights into the high rates of IAT failure and mortality observed among patients with cIAI. These data highlight the challenges associated with choosing IAT, the impact of MDR pathogens on IAT outcomes and the importance of tailoring IAT selection to account for local epidemiology and patient history.
dc.identifier.doi10.2147/IDR.S184116
dc.identifier.issn1178-6973
dc.identifier.pmcPMC6362915
dc.identifier.pmid30774399
dc.identifier.pubmedURLhttps://pmc.ncbi.nlm.nih.gov/articles/PMC6362915/pdf
dc.identifier.unpaywallURLhttps://www.dovepress.com/getfile.php?fileID=47804
dc.identifier.urihttps://hdl.handle.net/10668/27975
dc.journal.titleInfection and drug resistance
dc.journal.titleabbreviationInfect Drug Resist
dc.language.isoen
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.organizationSAS - Hospital Universitario Virgen Macarena
dc.organizationInstituto de Investigación Biomédica de Sevilla (IBIS)
dc.page.number329-343
dc.pubmedtypeJournal Article
dc.rightsAttribution-NonCommercial 4.0 International
dc.rights.accessRightsopen access
dc.rights.urihttp://creativecommons.org/licenses/by-nc/4.0/
dc.subjectclinical outcome
dc.subjectcomplicated intra-abdominal infection
dc.subjecthealth care associated
dc.subjectinitial antibiotic treatment
dc.subjectreal-world treatment patterns
dc.titleThe impact of initial antibiotic treatment failure: real-world insights in patients with complicated, health care-associated intra-abdominal infection.
dc.typeresearch article
dc.type.hasVersionVoR
dc.volume.number12

Files

Original bundle

Now showing 1 - 1 of 1
No Thumbnail Available
Name:
PMC6362915.pdf
Size:
250.64 KB
Format:
Adobe Portable Document Format